• BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

    Источник: Nasdaq GlobeNewswire / 23 фев 2024 07:00:00   America/New_York

    N/A
Опубликовать